Biological Buffers Market Size, Share, and Trends 2024 to 2033

Biological Buffers Market Size and Growth

The global biological buffers market size was USD 749.24 million in 2023, calculated at USD 805.73 million in 2024 and is expected to reach around USD 1,549.96 million by 2033, expanding at a CAGR of 7.54% from 2024 to 2033. The biological buffers market has a variety of products, including biological and pharmaceutical buffers, biochemical-grade buffers, and diagnostic-grade buffers, all of which contribute to its growth and vitality.

Biological Buffers Market Key Takeaways

• Europe led the global biological buffers market in 2023.
• Asia Pacific is expected to show significant growth in the market during the forecast period.
• By type, the phosphate type segment dominated the market in 2023 and is anticipated to experience rapid growth during the forecast period.
• By application, in 2023, the research institution segment dominated the market and is expected to experience the fastest growth during the projected period.

Market Overview

The biological buffers market involves the production and distribution of chemical compounds essential for maintaining pH stability in various biological and biochemical processes. These buffers are vital for numerous laboratory applications, such as cell culture, molecular biology, and protein biochemistry, driving demand throughout the life sciences industry.

The biological buffers market is complex and global, with biological buffers being indispensable in biological research, diagnostics, and analytical chemistry to guarantee precise and reliable experimental outcomes. By stabilizing pH in biological systems, even in the presence of strong acids or bases, these buffers ensure consistent pH levels.

Biological Buffers Market Growth Factors

• Increasing biopharmaceutical research is expected to fuel the biological buffers market shortly.
• Growth in diagnostic testing in healthcare can drive the biological buffers market growth during the forecast period.
• Strict quality control standards in pharmaceutical manufacturing and biotechnology industries will likely contribute to the expansion of the biological buffers market.
• The demand for customized buffers is increasing, which can lead to market growth.

Market Scope

Market Dynamics

Driver

Growing interest in biological buffers in life sciences

In recent years, the global biological buffers market has grown considerably due to increased demand in life sciences research and biopharmaceutical production. These buffers are important for maintaining a stable pH in solutions, which makes them essential for advancements in cell culture and other laboratory techniques.

There is a need for pH regulation across various industries, including healthcare and pharmaceuticals, hence driving the growth of the biological buffers market. Additionally, regulations govern the use of biological buffers in different applications. Any modifications to these regulations can impact on the market.

• In January 2024, Bionema Group, a leading developer of sustainable biocontrol solutions, announced a tender for the marketing of their innovative range of environmentally friendly biological products. These groundbreaking solutions are designed to address crop protection and plant health management in the Agriculture, Sports Turf Amenity, Horticulture, Agriculture, and Forestry sectors.

Restraint

Competition from alternative technologies

The presence of alternative pH control methods, like titratable acids and bases, might restrict the biological buffers market growth of biological buffers, particularly in applications where cost sensitivity is a concern. Moreover, disruptions in the supply chain, such as raw material shortages and logistical issues, can affect the availability and pricing of biological buffers and create challenges for both manufacturers and end-users.

Opportunities

Expanding academic and industrial laboratories

The increasing number of academic and industrial laboratories involved in life sciences research and bioprocessing is driving the demand for biological buffers. As these facilities expand, the need for buffers to maintain pH stability and enzymatic activity grows, which leads to higher consumption. This trend highlights the important role of buffers in supporting various laboratory applications. Moreover, the rising demand for blood and blood plasma for transfusions, along with ongoing vaccination programs for diseases like polio and rubella, is propelling the growth of the biological buffers market.

The expansion in the biopharmaceutical industry

The expanding biopharmaceutical industry increasingly depends on biological buffers during research, development, and production stages, driving the demand for high-quality buffers. These buffers are important for maintaining proper pH levels and enzymatic activity and ensuring the integrity and effectiveness of biologics. The demand for premium buffers is rising in parallel with the growth of biological buffers in the biological buffers market.

The growing use of cell culture techniques in drug discovery, vaccine production, and regenerative medicine highlights the necessity of biological buffers to maintain optimal pH conditions. This rising demand for buffers demonstrates their crucial role in ensuring the success and efficiency of various cellular processes by boosting the biological buffers market growth accordingly.

• In December 2023, Hanwha will re-enter the biopharma market, targeting biomaterials. to become the country’s sole producer of tris buffers, a key reagent used for medical experiments such as generic DNA tests. The business group is trying to keep up with Samsung, SK, and LG in the new growth market.

Type Insights

The phosphate type segment dominated the biological buffers market in 2023 and is anticipated to experience rapid growth during the forecast period. The segment is also anticipated to experience the most rapid growth during the forecast period. This can be attributed to factors such as economic development in emerging markets, evolving consumer trends and behaviors, and the increased need for biochemical research. The rising incidence of chronic diseases and the urgent need to develop effective treatments are also driving the demand for advanced biological buffers.

Due to the strong demand from the research and pharmaceutical sectors, the phosphate-type segment is projected to achieve the highest growth rate in the upcoming years. The increasing need for high-quality biological buffers is likely to boost the use of phosphate-type biological buffers in the global biological buffers market. These phosphate-type buffers are essential for numerous research applications, such as cell culture and protein purification, as they can maintain an optimal pH for enzyme activity.

End-user Insights

The research institution segment dominated the biological buffers market in 2023 and is expected to experience the fastest growth during the projected period. The market is anticipated to expand due to factors such as economic growth in developing economies, evolving consumer trends, and an increasing need for biochemical research.

• In September 2023, DESOTEC efficiently finalized the acquisition of Evoqua's Carbon Reactivation and Exchange Services Business.

Advanced biological buffers are vital for ensuring the stability and precision of these models, boosting the demand for high-quality buffers among research organizations. Moreover, the rising need for advanced research tools to investigate complex biological processes is driving the demand for biological buffers, which is expected to stimulate the growth of the research institution segment in the global biological buffers market.

Regional Insights

Europe led the global biological buffers market in 2023. Advancements in biopharmaceuticals and molecular biology research are driving market growth. Academic institutions and biotech firms are key contributors to this expansion. Partnerships between universities and buffer suppliers foster product innovation and increase market reach.

The region has also made significant investments in the pharmaceutical sector, which resulted in the development of state-of-the-art biological buffer facilities and technologies that produce high-quality buffers. Additionally, the European Union supports scientific research and development at both regional and international levels through various organizations and agencies that provide funding for biological buffer research.

• In April 2024, Cureline bolsters the Lithuanian biopharma industry with a CDMO launch. US-based biotech Cureline has launched Memel Biotech, a commercial-scale CDMO, to grow Lithuania’s biopharmaceutical industry. The contract development manufacturing organization (CDMO) will offer services for all three classes of advanced therapies: cell, gene, and tissue-engineered.

Asia Pacific is expected to show significant growth in the biological buffers market during the forecast period. The region's growth is propelled by growing investments in life sciences research and drug development. The surging demand for biopharmaceuticals and diagnostics is a significant driver. Collaborations with international pharmaceutical firms boost market presence and distribution networks. Furthermore, this expansion is attributed to rising investments in biotechnology, the growth of pharmaceutical manufacturing, and an increased emphasis on healthcare advancements. Key markets fueling this regional growth include China, India, and Japan.

• In December 2023, the Department of Biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC) announced the launch of 14 new biotech-based products developed by startups and entrepreneurs across verticals, including healthcare, diagnostics, medical devices, agriculture, and industrial biotechnology, during the 3rd edition of Global Bio-India, a mega international congregation on biotechnology.

Recent Developments

• In October 2023, Nijhuis Saur Industries (NSI) found the finishing touch of the acquisition of Pall Aria containerized devices, which constitutes a subset of Pall Water's cell water commercial enterprise in Europe.
• In February 2023, WuXi AppTec launched a new biological safety testing facility in Suzhou, China. This facility is equipped with the latest technology and will provide a wide range of biological safety testing services to clients in the Asia-Pacific region.
• In January 2023, Charles River Laboratories announced the acquisition of Eurofins Scientific's biological safety testing business. This acquisition will expand Charles River's capabilities in biological safety testing and help the company meet the growing demand for these services.
• In June 2023, CellTech Innovations unveiled "LysoBoost Plus," an enhanced cell lysis reagent with improved efficiency and compatibility across a wide range of cell types. The product incorporates a unique enzyme blend and optimized formulation to achieve higher yields of intracellular components, benefiting applications such as proteomics, genomics, and drug discovery.
• In January 2023, BioLysis Inc. introduced a breakthrough cell lysis technology, "CytoBreaker," which allows for faster and more efficient cell disruption. The technology utilizes advanced nanoparticle-based reagents for targeted cell lysis in various sample types.

Biological Buffers Market Companies

• Merck KGaA
• Thermo Fisher Scientific Inc
• Avantor
• GE Healthcare
• Santa Cruz Biotechnology, Inc.
• Lonza Group Ltd.
• Bio-Rad Laboratories, Inc
• F. Hoffmann-La Roche Ltd.
• Hamilton Company
• BASF SE

Segments covered in the report

By Type

• Phosphate Type
• Acetate Type
• TRIS Type
• Other Types

By End-User

• Research Institution
• Pharmaceutical Industry
• Other End-Users

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa